Description
Neurofibromatosis type 1 (NF1), also known as von Recklinghausen disease, is an inherited disorder primarily characterised by the growth of non-cancerous tumours of nerve tissue. Though it predominantly affects the skin and nervous system, it can have systemic manifestations, including the lungs. The pulmonary involvement in NF1, while less common, can significantly contribute to morbidity and mortality.
Pathogenesis
NF1 results from mutations in the NF1 gene, which produces the neurofibromin protein. Neurofibromin functions as a tumour suppressor, and when defective, it results in an abnormal proliferation of cells, leading to tumour formation.
In the lungs, the most typical manifestation of NF1 is interstitial lung disease (ILD). The exact pathogenesis of ILD in NF1 is still unclear. However, it seems to involve a combination of genetic susceptibility, immune dysregulation, and potentially, environmental factors.
Epidemiology, Risk Factors & Associations
Pulmonary involvement in NF1 is relatively rare. ILD, the most common pulmonary manifestation, occurs in less than 1% of patients. Having a family history of NF1 is a risk factor for pulmonary involvement.
Clinical Features
Clinical presentation of NF1 with lung involvement varies based on the type and severity of pulmonary manifestation. Symptoms may include:
- Chronic cough
- Dyspnoea
- Chest pain
- Haemoptysis
- Cyanosis
Complications
Pulmonary complications of NF1 may include:
- Respiratory failure
- Pulmonary hypertension (0.5%-2.3% of NF1 patients)
- Spontaneous pneumothorax (due to rupture of subpleural nodules)
- Interstitial lung disease (ILD)
Pathological Features
Morphology
In NF1-related lung pathology, interstitial fibrosis, pulmonary cysts, and changes related to pulmonary hypertension may be observed.
Histopathology
Histopathological examination of lung tissues may reveal interstitial fibrosis with patterns such as usual interstitial pneumonia, characteristic of ILD. Pulmonary nodules may show features consistent with neurofibromas.
Biochemistry
No specific biochemical markers have been identified for lung involvement in NF1.
Genetics
Mutations in the NF1 gene, located on chromosome 17, is the genetic hallmark of NF1. The role of these mutations in pulmonary involvement is yet to be fully understood.
Radiological Features
CT
Chest:
- Pulmonary nodules, typically well-defined and showing slow growth (<10%)
- Ground-glass opacities and interlobular septal thickening (<1%)
- Cystic changes (thin-walled) in upper lobe
- Enlargement of pulmonary arteries in cases of pulmonary hypertension (2%)
- Pulmonary fibrosis: Reticulation, traction bronchiectasis, basilar honeycombing
Mediastinum:
- Neurogenic neoplasm: Well-defined paravertebral mass, spherical or fusiform, variable contrast enhancement
- Meningocele: Water attenuation, well-circumscribed paravertebral mass
- Pulmonary hypertension: Pulmonary trunk (>29 mm), mosaic attenuation
Bone:
- Scoliosis: Most common osseous complication of NF1
- Vertebral scalloping, neuroforaminal widening, transverse process spindling, rib penciling of neuroforamen
Chest X-Ray
- Interstitial markings, nodular patterns, or signs of pulmonary hypertension.
Grading and Staging
There is no specific grading or staging system for pulmonary involvement in NF1.
Differential Diagnosis
- Lymphangioleiomyomatosis (LAM): Characterised by diffuse cystic lung disease, primarily affects women of reproductive age. The presence of tuberous sclerosis complex may help differentiate it from NF1.
- Birt-Hogg-Dube Syndrome: Characterised by lung cysts, renal cancer, and skin fibrofolliculomas.
- Langerhans cell histiocytosis: Can cause cystic lung disease. Biopsy showing Langerhans cells helps in diagnosis.
- Sarcoidosis: Granulomatous disease that may show interstitial lung involvement.
Management
- Management of NF1 with lung involvement is multidisciplinary and generally involves pulmonologists, radiologists, and geneticists.
- Treatment is largely supportive and aimed at controlling symptoms.
- Therapeutic options include bronchodilators, oxygen therapy, pulmonary rehabilitation, and in severe cases, lung transplantation.
- Regular follow-up with imaging studies is crucial to monitor progression